STT FA Bio 'GID' GI DYNAMICSDeveloper and marketer of...

STT FA Bio 'GID' GI DYNAMICS

Developer and marketer of EndoBarrier®, a breakthrough device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S.

Revenue increased to approximately US$0.5 million for the 3rd Quarter compared to approximately US$0.1 million for the same period last year. The increase in the Company’s revenue in the Quarter was primarily a result of a 163% increase in revenue from sales in Europe and revenue from sales in the Middle East with no corresponding sales in the same period last year.

GI Dynamics is conducting a pivotal clinical trial of EndoBarrier (the ENDO Trial) in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese.

GI Dynamics Announces EndoBarrier® Therapy Data to be Presented at International Diabetes Foundation World Diabetes Conference December 3, 2013.

Has cash of $44m in the bank

I'm expecting a turn around in the SP as this company move forward.